PCRX Relative Valuation
PCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PCRX is overvalued; if below, it's undervalued.
Historical Valuation
Pacira Biosciences Inc (PCRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.12 is considered Undervalued compared with the five-year average of 13.04. The fair price of Pacira Biosciences Inc (PCRX) is between 33.37 to 64.14 according to relative valuation methord. Compared to the current price of 24.14 USD , Pacira Biosciences Inc is Undervalued By 27.66%.
Relative Value
Fair Zone
33.37-64.14
Current Price：24.14
27.66%
Undervalued
7.06
PE
1Y
3Y
5Y
Trailing
Forward
5.35
EV/EBITDA
Pacira Biosciences Inc. (PCRX) has a current EV/EBITDA of 5.35. The 5-year average EV/EBITDA is 9.12. The thresholds are as follows: Strongly Undervalued below 2.77, Undervalued between 2.77 and 5.95, Fairly Valued between 12.30 and 5.95, Overvalued between 12.30 and 15.47, and Strongly Overvalued above 15.47. The current Forward EV/EBITDA of 5.35 falls within the Undervalued range.
6.39
EV/EBIT
Pacira Biosciences Inc. (PCRX) has a current EV/EBIT of 6.39. The 5-year average EV/EBIT is 10.15. The thresholds are as follows: Strongly Undervalued below 3.51, Undervalued between 3.51 and 6.83, Fairly Valued between 13.47 and 6.83, Overvalued between 13.47 and 16.78, and Strongly Overvalued above 16.78. The current Forward EV/EBIT of 6.39 falls within the Undervalued range.
1.32
PS
Pacira Biosciences Inc. (PCRX) has a current PS of 1.32. The 5-year average PS is 2.83. The thresholds are as follows: Strongly Undervalued below 0.09, Undervalued between 0.09 and 1.46, Fairly Valued between 4.20 and 1.46, Overvalued between 4.20 and 5.57, and Strongly Overvalued above 5.57. The current Forward PS of 1.32 falls within the Undervalued range.
4.71
P/OCF
Pacira Biosciences Inc. (PCRX) has a current P/OCF of 4.71. The 5-year average P/OCF is 10.11. The thresholds are as follows: Strongly Undervalued below -0.06, Undervalued between -0.06 and 5.02, Fairly Valued between 15.19 and 5.02, Overvalued between 15.19 and 20.28, and Strongly Overvalued above 20.28. The current Forward P/OCF of 4.71 falls within the Undervalued range.
5.58
P/FCF
Pacira Biosciences Inc. (PCRX) has a current P/FCF of 5.58. The 5-year average P/FCF is 13.92. The thresholds are as follows: Strongly Undervalued below -7.22, Undervalued between -7.22 and 3.35, Fairly Valued between 24.49 and 3.35, Overvalued between 24.49 and 35.06, and Strongly Overvalued above 35.06. The current Forward P/FCF of 5.58 falls within the Historic Trend Line -Fairly Valued range.
Pacira Biosciences Inc (PCRX) has a current Price-to-Book (P/B) ratio of 1.43. Compared to its 3-year average P/B ratio of 1.63 , the current P/B ratio is approximately -12.57% higher. Relative to its 5-year average P/B ratio of 2.56, the current P/B ratio is about -44.13% higher. Pacira Biosciences Inc (PCRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 12.73%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 8.78% , the current FCF yield is about -100.00% lower.
1.42
P/B
Median3y
1.63
Median5y
2.56
11.93
FCF Yield
Median3y
12.73
Median5y
8.78
Competitors Valuation Multiple
The average P/S ratio for PCRX's competitors is 0.61, providing a benchmark for relative valuation. Pacira Biosciences Inc Corp (PCRX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 6.49%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PCRX increased by 27.28% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 22.68 to 50.88.
The secondary factor is the Revenue Growth, contributed 6.49%to the performance.
Overall, the performance of PCRX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Pacira Biosciences Inc (PCRX) currently overvalued or undervalued?
What is Pacira Biosciences Inc (PCRX) fair value?
How does PCRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Pacira Biosciences Inc (PCRX) as of Dec 05 2025?
What is the current FCF Yield for Pacira Biosciences Inc (PCRX) as of Dec 05 2025?
What is the current Forward P/E ratio for Pacira Biosciences Inc (PCRX) as of Dec 05 2025?